John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
References
1. Xarelto. [package insert]. Titusville, NJ; Janssen Pharmaceuticals,
Inc, 2011.
2. Kubitza D et al. Safety, pharmacodynamics, and pharmacokinetics
of single doses of BAY 59-7939, an oral, direct factor Xa
inhibitor. Clin Pharmacol Ther. 2005;78:412-21.
3. Mueck W eta l. Population pharmacokinetics and pharmacodynamics
of once- and twice-daily rivaroxaban for the prevention of venous
thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-461.
4. Kubitza D et al. Effects of renal impairment on the
pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral, direct
Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703-12.